Allogene Therapeutics's total assets for Q2 2025 were $470.59M, a decrease of -7.36% from the previous quarter. ALLO total liabilities were $126.03M for the fiscal quarter, a 2.81% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.